BioSpace News Archive

Quipt Home Medical Corp. is very pleased to announce it has executed a non-binding letter of intent to acquire an arm’s length private respiratory care company in the Midwestern United States reporting unaudited trailing 12-month annual revenues of approximately $13 million, $1.6 million in net income, and positive Adjusted EBITDA.

Humacyte, Inc. today announced positive results from a preclinical study of the small-diameter (3.5mm) HAV in a primate model simulating pediatric heart disease were presented at the American Heart Association’s (AHA) Scientific Sessions 2021.

HemoShear Therapeutics, Inc. announced today that a second target identified utilizing the company’s REVEAL-Tx ™ human disease modeling platform has been selected by Takeda Pharmaceutical Company Limited

Nutriband Inc., a company engaged in the development of pharmaceutical products, contract research and development services, and the manufacture of transdermal products, has commenced the development of its lead product candidate, AVERSA™ Fentanyl, an abuse deterrent fentanyl transdermal system.

Sonoma Biotherapeutics, an immune tolerance company focused on the development of novel regulatory T cell therapies for autoimmune and inflammatory disease, announced the appointment of Heidi Hagen, MBA as Chief Technical Officer.

Biovica, active in cancer diagnostics, announced that the results of a DiviTum®TKa budget impact model have been published in the Journal of Medical Economics.

MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced financial results for the third quarter ended September 30, 2021.

HotSpot Therapeutics, Inc. today announced that company leadership will deliver a corporate overview at the Piper Sandler 33rd Annual Healthcare Conference

Volastra Therapeutics today announced the expansion of its leadership team with key new hires in business development and translational science, as well as the promotion and expansion of leaders to helm its biology, immunology, data science and chemistry functions.

StageZero Life Sciences, a vertically-integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announced its third-quarter financial results for the three months ended September 30, 2021, and provided an update on its business progress.